Short-course adjuvant trastuzumab will increase cure rates in patients with human epidermal growth factor receptor 2-positive breast cancer
S Afr Med J
.
2017 Jul 28;107(8):654-655.
doi: 10.7196/SAMJ.2017.v107i8.12673.
Author
Raymond Pierre Abratt
1
Affiliation
1
Head of Clinical Governance, Independent Clinical Oncology Network, Cape Town, South Africa; Emeritus Professor of Radiation Oncology, Faculty of Health Sciences, University of Cape Town, South Africa. raymond.abratt@uct.ac.za.
PMID:
28809611
DOI:
10.7196/SAMJ.2017.v107i8.12673
No abstract available
Publication types
Editorial
Comment
MeSH terms
Breast Neoplasms*
Humans
Receptor, ErbB-2*
Trastuzumab
Substances
ERBB2 protein, human
Receptor, ErbB-2
Trastuzumab